Clinical Analysis of Partial Ureteral Resection for Primary Ureteral Carcinoma(Report of 14 Cases)
Jianye LIU,Zike QIN,Hui HAN,Zhuowei LIU,Yonghong LI,Kai YAO,Pei DONG,Keshi LU,Zhenzhou XU,Zhiling ZHANG,Fangjian ZHOU
DOI: https://doi.org/10.3969/j.issn.1001-1420.2011.10.010
2011-01-01
Journal of Clinical Urology
Abstract:Objective:To evaluate the feasibility and effi cacy of partial ureteral resection for primary ureteral car-cinoma.Method:From April 2000 to April 2010,14 cases of primary ureteral carcinoma were retrospectively investigated.This series included 14 cases of primary ureteral carcinoma who had undergone partial ureteral resection, and then restored the continuity of the ureter.The middle ureteral cancer used the ileum restored the continuity of the ureter,and the lower ureteral cancer used the bladder flap restored the continuity of the ureter.And 29 cases who had undergone radical nephroureterectomy for primary ureteral carcinoma(control group)at the same time. The incidence of bladder cancer after operation,the disease specific survival rate were compared between the 2 groups.Result:Follow-up was available in 12 cases of partial ureteral resection group,the incidence of bladder cancer after operation is 16.7%(2/12).the disease specific 1-year survival rate is 91.7%(11/12).and the disease specific 5-year survival rate is 75.0%.Follow-up was available in 24 cases of control group,the incidence of bladder cancer after operation is 12.5%(3/24),the disease specific 1-year survival rate is 95.8%(23/24).the disease specific 5-year survival rate is 79.2%.There was no obvious difference in the incidence of bladder cancer after operation, the disease specific 1-year and 5-year survival rate between the 2 groups(P>0.05).Conclusion:Based on disease characteristics of synchronous and metachronous and bilateral of the ureteral carcinoma,and with strictly follow -up after partial ureteral resection for primary ureteral carcinoma,partial ureteral resection and restore the continuity of the ureter can be used in properly selected patients with middle and lower ureteral carcinomas.